Dual-Action Inhibitor Shows Promise in Eradicating Multiple Cancer Types in Animal Studies
In a significant breakthrough for oncology, researchers have developed a novel drug candidate capable of simultaneously blocking two key proteins that drive cancer growth and metastasis. In animal trials, the combination of this dual inhibitor with immunotherapy led to the complete eradication of several aggressive tumor types, with no signs of recurrence even after cancer cells were reintroduced.
The study, conducted by a joint research team from Johns Hopkins University and the University of Maryland, focuses on the inhibition of Hypoxia-Inducible Factors 1 and 2 (HIF-1 and HIF-2). These proteins act as “master switches” within the low-oxygen environments typical of tumors, facilitating cancer cell growth, the creation of new blood vessels to supply nutrients, and the ability of tumors to evade the immune system. Due to the fact that high levels of HIF-1 and HIF-2 are often linked to lower survival rates and decreased effectiveness of conventional treatments, they are considered critical indicators for patient prognosis across various cancers.
Accelerating Drug Discovery with SILCS Technology
To develop a molecule that could bind to both HIF-1 and HIF-2, the research team utilized an advanced drug design technology known as SILCS (Site-Identification by Ligand Competitive Saturation). By analyzing the crystal structure of HIF-2, the team was able to predict which molecules had the highest probability of binding effectively.
The use of SILCS significantly streamlined the discovery process. Rather than manually testing millions of compounds, the researchers were able to narrow the field to a few hundred high-potential candidates. This approach led to the identification of several compounds—now termed “dual HIF-1/2 inhibitors”—that not only bind to both factors but too induce their degradation and block the activation of target genes.
Breakthrough Results in Animal Models
The efficacy of the dual HIF-1/2 inhibitors was rigorously tested in mouse models. When administered as a standalone treatment, the inhibitors suppressed the growth of tumors in breast, colon, head and neck, melanoma, and prostate cancers. The researchers observed a marked reduction in angiogenesis—the formation of new blood vessels that feed tumors—and a decrease in the cancer cells’ ability to invade surrounding healthy tissues.
The most striking results occurred when the dual inhibitor was used in tandem with immunotherapy. This combination resulted in the complete removal of breast, colon, melanoma, and prostate tumors. Notably, the tumors did not return even after the researchers attempted to reintroduce cancer cells into the subjects.
Expanding the Horizon of Targeted Therapy
Current medical options for targeting these proteins are limited. For instance, Belzutifan, a drug that selectively inhibits only HIF-2, is currently approved for treating certain cancers, such as advanced renal cell carcinoma. Although, the ability to block both HIF-1 and HIF-2 simultaneously represents a more comprehensive approach to neutralizing the tumor’s survival mechanisms.
These findings, published on April 2 in the Journal of Experimental Medicine, suggest a potential path forward for treating cancers that have previously been resistant to immunotherapy. By dismantling the protective environment created by HIF proteins, this dual-action approach could fundamentally change how clinicians target “impregnable” tumors in the future.
